Bone Biologics (Bone Biologics) Total Current Assets : $3.84 Mil (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Bone Biologics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Bone Biologics's total current assets for the quarter that ended in Mar. 2024 was $3.84 Mil.

Bone Biologics Total Current Assets Historical Data

The historical data trend for Bone Biologics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bone Biologics Total Current Assets Chart

Bone Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

0.03

6.68

8.50

3.74

Bone Biologics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															6.78	7.62	4.98	3.74	3.84

Bone Biologics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Bone Biologics's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	3.027	+	0.329	+	0	+	0.382
	=	3.74

Bone Biologics's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	3.228	+	0.329	+	0	+	0.283
	=	3.84

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Bone Biologics (NAS:BBLG) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Bone Biologics's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3.228	-	0.165	+	0.75 * 0	+	0.5 * 0
=	3.06

Bone Biologics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Bone Biologics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Bone Biologics (Bone Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bone Biologics Corp (NAS:BBLG) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Burlington Woods Drive, Suite 100, Burlington, MA, USA, 01803

Website

https://www.bonebiologics.com

Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has application in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

Executives

Deina H Walsh	officer: Chief Financial Officer	175, MAY STREET, EDISON NJ 08837
Jeff Frelick	officer: Chief Operating Officer	1 FOX RUN LANE,, LEXINGTON MA 02420
Knight Insurance Company, Ltd	10 percent owner	4751 WILSHIRE BLVD.,, SUITE 111, LOS ANGELES CA 90010
Siddhesh Rajendra Angle	director	481 MONMOUTH ST, UNIT G,, JERSEY CITY NJ 07302
Erick Lucera	director	138 THISTLE ROAD, NORTH ANDOVER MA 08145
Don Hankey	director, 10 percent owner, officer: Chairman of the Board	4751 WILSHIRE BLVD., SUITE 110, LOS ANGELES CA 90010
Bret Hankey	director	4751 WILSHIRE BLVD. #110, LOS ANGELES CA 90010
Hankey Capital, Llc	10 percent owner	4751 WILSHIRE BLVD., #110, LOS ANGELES CA 90010
Don Hankey Trust	10 percent owner	4751 WILSHIRE BLVD., #110, LOS ANGELES CA 90010
Amir F Heshmatpour	10 percent owner	269 S. BEVERLY DRIVE, STE #1600, BEVERLY HILLS CA 90212
Musculoskeletal Transplant Foundation, Inc.	director	175 MAY STREET, SUITE 300, EDISON NJ 08837
Benjamin Wu	director	2740 LORAIN ROAD, SAN MARINO CA 91108
La Neve Stephen R.	director, officer: CEO and President	106 MCCOOL BLVD, WEST CHESTER PA 19380
George A Oram	director	12 EDGEMONT LANE, BEDMINSTER NJ 07921
Jim Delshad	director	132 S. MAPLE DR., BEVERLY HILLS CA 90212